Revenue by source
MS Product Revenues$4.04BTYSABRI product$1.67BSPINRAZA$1.55BFumarate$1.43BInterferon$945.60M
| Segment | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| MS Product Revenues | - | - | - | - | - | - | - | - | $8.60B | $8.53B | $7.83B | $6.10B | $5.43B | $4.66B | $4.35B | $4.04B |
| TYSABRI product | $900.20M | $1.08B | $1.14B | $1.53B | $1.96B | $1.89B | $1.96B | $1.97B | $1.86B | $1.89B | $1.95B | $2.06B | $2.03B | $1.88B | $1.72B | $1.67B |
| SPINRAZA | - | - | - | - | - | - | $4.60M | $883.70M | $1.72B | $2.10B | $2.05B | $1.91B | $1.79B | $1.74B | $1.57B | $1.55B |
| Fumarate | - | - | - | - | - | - | - | - | - | - | $3.91B | $2.36B | $2.00B | $1.59B | $1.60B | $1.43B |
| Interferon | - | - | - | - | - | - | - | - | $2.36B | $2.10B | $1.88B | $1.57B | $1.31B | $1.11B | $968.00M | $945.60M |
Revenue by country
UNITED STATES$2.37BNon-US$3.57BEurope$0.00Asia$0.00GERMANY$0.00
| Segment | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| UNITED STATES | $1.74B | $1.95B | $2.18B | $1.90B | $2.43B | $2.91B | $3.17B | $3.29B | $1.90B | $6.71B | $5.90B | $3.81B | $3.47B | $3.14B | $3.24B | $2.37B |
| Non-US | $1.73B | $1.88B | $1.99B | $1.96B | $2.64B | $2.64B | $2.77B | $3.34B | - | $4.67B | $4.79B | $5.04B | $4.52B | - | $3.98B | $3.57B |
| Europe | - | - | - | - | - | - | - | - | $3.37B | - | - | - | - | $2.13B | - | - |
| Asia | - | - | - | - | - | - | - | - | $281.20M | - | - | - | - | $649.40M | - | - |
| GERMANY | - | - | - | - | - | - | - | - | - | - | - | - | - | $868.00M | - | - |